All In Biotech

Investigational drug · Phase 3

1.0% IP-001

Also called: IP-001

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "1.0% IP-001"

First trial start

2022

Nov 29, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "1.0% IP-001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Colorectal Cancer (CRC)
  • Colon Cancer Liver Metastases
  • Rectal Cancer
  • Rectal Cancer With Liver Metastases
  • Colorectal Liver Metastasis (CRLM)
  • Metastatic Solid Tumor
  • Colon Cancer
  • Nonsmall Cell Lung Cancer
  • Soft Tissue Sarcoma

Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Sarcoma · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "1.0% IP-001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Colorectal Cancer (CRC)

  • RMC-6291ElironrasibPhase 23 trials

    Revolution Medicines, Inc. · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer

  • GI-102Phase 22 trials

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)

  • BMS-986523Phase 21 trial

    Bristol Myers Squibb · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

  • BPI-572270Phase 21 trial

    Betta Pharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

  • GEN1042Phase 21 trial

    Genmab · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

  • ImofinostatABT-301, MPT0E028Phase 21 trial

    Anbogen Therapeutics, Inc. · Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)

  • JYP0015Phase 21 trial

    Guangzhou JOYO Pharma Co., Ltd · Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC)

  • SYS6062Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.